Quinolone-based third-line therapy for Helicobacter pylori eradication

Toshihiro Nishizawa, Hidekazu Suzuki, Toshifumi Hibi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalJournal of Clinical Biochemistry and Nutrition
Volume44
Issue number2
DOIs
Publication statusPublished - 2009 Mar

Fingerprint

Quinolones
Helicobacter pylori
Furazolidone
Rifabutin
Proton Pump Inhibitors
Amoxicillin
Therapeutics
Pharmaceutical Preparations
Testing
gatifloxacin

Keywords

  • Helicobacter pylori
  • Quinolone
  • Third-line therapy

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Quinolone-based third-line therapy for Helicobacter pylori eradication. / Nishizawa, Toshihiro; Suzuki, Hidekazu; Hibi, Toshifumi.

In: Journal of Clinical Biochemistry and Nutrition, Vol. 44, No. 2, 03.2009, p. 119-124.

Research output: Contribution to journalArticle

Nishizawa, Toshihiro ; Suzuki, Hidekazu ; Hibi, Toshifumi. / Quinolone-based third-line therapy for Helicobacter pylori eradication. In: Journal of Clinical Biochemistry and Nutrition. 2009 ; Vol. 44, No. 2. pp. 119-124.
@article{22a474740d904570926d249efd31406b,
title = "Quinolone-based third-line therapy for Helicobacter pylori eradication",
abstract = "Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60{\%} to 84{\%}. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.",
keywords = "Helicobacter pylori, Quinolone, Third-line therapy",
author = "Toshihiro Nishizawa and Hidekazu Suzuki and Toshifumi Hibi",
year = "2009",
month = "3",
doi = "10.3164/jcbn.08-220R",
language = "English",
volume = "44",
pages = "119--124",
journal = "Journal of Clinical Biochemistry and Nutrition",
issn = "0912-0009",
publisher = "The Society for Free Radical Research Japan",
number = "2",

}

TY - JOUR

T1 - Quinolone-based third-line therapy for Helicobacter pylori eradication

AU - Nishizawa, Toshihiro

AU - Suzuki, Hidekazu

AU - Hibi, Toshifumi

PY - 2009/3

Y1 - 2009/3

N2 - Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

AB - Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

KW - Helicobacter pylori

KW - Quinolone

KW - Third-line therapy

UR - http://www.scopus.com/inward/record.url?scp=63049096015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049096015&partnerID=8YFLogxK

U2 - 10.3164/jcbn.08-220R

DO - 10.3164/jcbn.08-220R

M3 - Article

VL - 44

SP - 119

EP - 124

JO - Journal of Clinical Biochemistry and Nutrition

JF - Journal of Clinical Biochemistry and Nutrition

SN - 0912-0009

IS - 2

ER -